MedTrace Logo

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

NCT04504604 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2024-08-09

No results posted yet for this study

Summary

This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.

Conditions

Interventions

DIAGNOSTIC_TEST

FoundationOne CDx and FoundationOne Liquid CDx

Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.

Sponsors & Collaborators

Principal Investigators

  • Razelle Kurzrock, M.D. · Medical College of Wisconsin

  • Vivek Subbiah, M.D. · SCRI Development Innovations, LLC

  • Shumei Kato, M.D. · University of California, San Diego

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2025-09-30
Completion
2025-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04504604 on ClinicalTrials.gov